… patients with disease progression after cytotoxic chemotherapy might benefit from erlotinib
monotherapy. … - or third-line erlotinib monotherapy for elderly patients with EGFR-wt advanced …

… of erlotinib, designed to allow access to erlotinib monotherapy … older patients (≥70 years)
who participated; this report describes outcomes among elderly patients who received erlotinib …

… second- or third-line erlotinib treatment in elderly patients with NSCLC. The primary endpoint
… received platinum-based combination chemotherapy and 3 patients received monotherapy …

… II study of erlotinib as first-line treatment in Asian elderly patients with … patients, erlotinib
monotherapy was effective and well tolerated as a first-line treatment in Asian elderly patients …

… The potential beneficial interaction between erlotinib and … of sequential erlotinib and
gemcitabine versus gemcitabine monotherapy as first-line therapy in elderly or ECOG PS-2 patients …

… with pretreated NSCLC were randomized to four separate phase II targeted therapies
including erlotinib monotherapy, clinical outcomes of patients aged >65 years were comparable …

… population derived especially from two Italian phase III trials: in the ELVIS study [4], a
monotherapy with vinorelbine demonstrated a significant survival benefit over best supportive care …

… Erlotinib was effective and well tolerated as a first-line treatment in the elderly patients with
… it demonstrates that erlotinib can be a valid treatment option for patients who are unsuitable …

… monotherapy arm, nine of the patients classified as Good and three classified as Poor
went on to receive erlotinib therapy as a second-line therapy. Outcomes on the erlotinib and …

… , no prospective erlotinib data focusing on elderly patients with EGFR mutations are available
and the present study demonstrates the benefit of erlotinib for those patients for the first …